RMTI
Price:
$3.89
Market Cap:
$120.71M
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1998-01-27
Stock Exchange
NASDAQ
Ticker
RMTI
According to Rockwell Medical, Inc.’s latest financial reports and current stock price. The company's current ROE is -21.95%. This represents a change of 286.37% compared to the average of -5.68% of the last 4 quarters.
The mean historical ROE of Rockwell Medical, Inc. over the last ten years is -210.20%. The current -21.95% ROE has changed -89.56% with respect to the historical average. Over the past ten years (40 quarters), RMTI's ROE was at its highest in in the March 2022 quarter at 160.14%. The ROE was at its lowest in in the December 2021 quarter at -352.70%.
Average
-210.20%
Median
-86.10%
Minimum
-1382.01%
Maximum
-23.14%
Discovering the peaks and valleys of Rockwell Medical, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.38%
Maximum Annual ROE = -23.14%
Minimum Annual Increase = -99.62%
Minimum Annual ROE = -1382.01%
Year | ROE | Change |
---|---|---|
2023 | -39.64% | -72.83% |
2022 | -145.88% | -89.44% |
2021 | -1382.01% | 1.38% |
2020 | -93.45% | -38.90% |
2019 | -152.95% | 29.86% |
2018 | -117.78% | 49.55% |
2017 | -78.76% | 110.61% |
2016 | -37.39% | 61.61% |
2015 | -23.14% | -25.46% |
2014 | -31.04% | -99.62% |
The current ROE of Rockwell Medical, Inc. (RMTI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-522.51%
5-year avg
-362.79%
10-year avg
-210.20%
Rockwell Medical, Inc.’s ROE is less than Lifecore Biomedical, Inc. (17.23%), less than Kamada Ltd. (6.18%), greater than Intra-Cellular Therapies, Inc. (-9.93%), less than Agile Therapeutics, Inc. (104.04%), less than Eagle Pharmaceuticals, Inc. (17.39%), greater than Regencell Bioscience Holdings Limited (-48.12%), less than Procaps Group S.A. (97.17%), greater than Cumberland Pharmaceuticals Inc. (-34.74%), greater than Incannex Healthcare Limited (-73.90%), less than Aquestive Therapeutics, Inc. (62.93%), greater than Evoke Pharma, Inc. (-964.02%), less than Adamis Pharmaceuticals Corporation (0.93%), greater than Guardion Health Sciences, Inc. (-71.26%), greater than AcelRx Pharmaceuticals, Inc. (-48.62%), greater than China SXT Pharmaceuticals, Inc. (-83.62%), greater than Biofrontera Inc. (-477.13%), greater than FSD Pharma Inc. (-94.58%), less than Acorda Therapeutics, Inc. (485.80%), greater than Lucy Scientific Discovery Inc. (-377.80%), less than Collegium Pharmaceutical, Inc. (49.14%), less than Phibro Animal Health Corporation (0.91%), less than ANI Pharmaceuticals, Inc. (6.02%), less than Silver Spike Investment Corp. (5.74%),
Company | ROE | Market cap |
---|---|---|
17.23% | $220.59M | |
6.18% | $344.30M | |
-9.93% | $9.14B | |
104.04% | $10.43M | |
17.39% | $9.72M | |
-48.12% | $105.66M | |
97.17% | $200.83M | |
-34.74% | $16.07M | |
-73.90% | $45.53M | |
62.93% | $468.96M | |
-964.02% | $4.69M | |
0.93% | $7.25M | |
-71.26% | $4.35M | |
-48.62% | $14.58M | |
-83.62% | $1.66M | |
-477.13% | $5.54M | |
-94.58% | $66.67K | |
485.80% | $821.03K | |
-377.80% | $906.91K | |
49.14% | $1.05B | |
0.91% | $906.07M | |
6.02% | $1.18B | |
5.74% | $66.72M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rockwell Medical, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rockwell Medical, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Rockwell Medical, Inc.'s ROE?
How is the ROE calculated for Rockwell Medical, Inc. (RMTI)?
What is the highest ROE for Rockwell Medical, Inc. (RMTI)?
What is the 3-year average ROE for Rockwell Medical, Inc. (RMTI)?
What is the 5-year average ROE for Rockwell Medical, Inc. (RMTI)?
How does the current ROE for Rockwell Medical, Inc. (RMTI) compare to its historical average?